Last Price
176.82
Today's Change
-0.96 (0.53%)
Day's Change
176.50 - 178.76
Trading Volume
108,723
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Krish S. Krishnan M.B.A., M.S. Mr. Krish S. Krishnan M.B.A., M.S.
Full Time Employees: 229 229
IPO Date: 2017-09-20 2017-09-20
CIK: 0001711279 0001711279
ISIN: US5011471027 US5011471027
CUSIP: 501147102 501147102
Beta: 0.82 0.82
Last Dividend: 0.00 0.00
Dcf Diff: 148.59 148.59
Dcf: 29.19 29.19
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.